Study of Erenumab (AMG 334) in Women With Hot Flashes

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
The primary objective of this study was to evaluate the frequency of moderate to severe daily hot flashes 4 weeks after a single dose of erenumab (AMG 334) in women with hot flashes associated with menopause.
Epistemonikos ID: b5b0eb782c129cdcf866a37fa828dc0334a77d30
First added on: May 11, 2024